It is currently Mon Apr 23, 2018 8:16 pm

News News of Drug Pipeline

Site map of Drug Pipeline » Forum : Drug Pipeline

A board to discuss future MS therapies in early stage (Phase I or II) trials.

gene-based interferon beta

This would have been far more exciting if they could have made this discovery 10 years ago.

Gene-Based Intramuscular Interferon-beta Therapy for Experimental Autoimmune Encephalomyelitis.

Mol Ther. 2006 Jun 15;
Jaini R, Hannaman D, Johnson JM, Bernard RM, Altuntas CZ, Delasalas MM, Kesaraju P, Luxembourg A, Evans CF, Tuohy VK.
Department of Immunology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.

In contrast to serial injections of recombinant interferon-beta (IFN-beta) for long-term therapy of ...
Read more : gene-based interferon beta | Views : 1583 | Replies : 0

News: Nutra Pharma to Acquire ReceptoPharm

Nutra Pharma annouced today that ReceptoPharm signed a letter of intent to be fully acquired by Nutra Pharma.

More details at Thought this board would find this interesting news...
Read more : News: Nutra Pharma to Acquire ReceptoPharm | Views : 1955 | Replies : 2

Change of name

PharmaFrontiers, developer of Tovaxin, has changed its name to Opexa.
Read more : Change of name | Views : 1938 | Replies : 4



I'm losing track of all these drugs - not sure if this one has been posted before.


Preclinical studies have produced data which supports the potential of Micromet's investigational human antibody MT203 for the treatment of inflammatory conditions such as rheumatoid arthritis and multiple sclerosis.
The study, published in Molecular Immunology, describes one of the first human antibodies potently neutralizing human GM-CSF.

GM-CSF is a key pro-inflammatory cytokine responsible for the proliferation, activation, ...
Read more : mt203 | Views : 1620 | Replies : 1

Interesting startup company

I like the viral angle...

Biotech startup VLST gets $55 million

Seattle P-I - June 16 - VLST Corp., a tiny Seattle biotechnology company that was formed by two former Amgen researchers, has scored $55 million in venture capital that it will use to develop experimental treatments for diseases such as lupus, psoriasis and multiple sclerosis.

The financing -- the 16th-biggest venture capital deal in the country this year and the largest in Washington state ...
Read more : Interesting startup company | Views : 1776 | Replies : 0

Next life - make me a mouse

Oral therapy which is good on mice.

Ian ... June15.asp
Read more : Next life - make me a mouse | Views : 1879 | Replies : 3

PharmaFrontiers and Tovaxin

Here's some updated/new info about the company and Tovaxin. Lots of stock talk but keep scrolling as they get into the drug.

Finding the funds to fight a disease
Multiple sclerosis therapy lures some investors

Copyright 2006 Houston Chronicle

David McWilliams is convinced PharmaFrontiers will be able to create a cost-competitive individualized therapy for people with multiple sclerosis.

But McWilliams knows he won't be able to reach this ambitious goal if ...
Read more : PharmaFrontiers and Tovaxin | Views : 2191 | Replies : 1

Research 2006

Nothing new - but an interesting interview with the NMSS Head of Research.

The Rituximab results should certainly be of interest for those with progressive forms of MS. ... ipt_01.pdf

Read more : Research 2006 | Views : 2088 | Replies : 1

Clinical trials in MS

List from NMSS

The list looks very impressive, although the CRABs still appear too often for my liking. They, to me, represent the Model T Fords - they've had their day and now we want somthing akin to a Formula 1 racing car.

Interesting that Bone Marrow Transplanation studies appear to be on the rise, as do trials of some of the heavy duty chemo drugs. Surely, some on the list will deliver! (fingers crossed) ...
Read more : Clinical trials in MS | Views : 1847 | Replies : 0


Here's a drug from German company 4SC AG.

Martinsried – 4SC AG, a drug discovery and development company specialising in research and development of therapeutic agents, announced today that they have successfully concluded Phase I studies for the small molecule product candidate SC12267 for treatment of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. A safe and well tolerated dose was determined in these studies, which did not cause any relevant side effects ...
Read more : SC12267 | Views : 1720 | Replies : 1


Login  •  Register


Total posts 242880 • Total topics 26657 • Total members 17828

Contact us | Terms of Service